Icotrokinra demonstrated superiority to placebo and deucravacitinib in the treatment of adults and adolescents with moderate ...

A recent review explored the benefits of biosimilars for patients with moderate to severe chronic plaque psoriasis.

Early apremilast initiation is associated with reduced psoriasis activity and burden compared with late initiation or continued topical therapy use.

A slightly more premium option, and one that includes the same colloidal oatmeal as the Aveeno cream above, Dr Armstrong ...

Bristol Myers Squibb Co said on Tuesday its experimental plaque psoriasis oral drug proved more effective in clearing moderate to severe cases of the skin condition than placebo or Amgen Inc's Otezla ...

Still given JNJ has most of the rights to market and sell icontrokinra, is there any pressing need to complete a full, ...

Psoriasis can involve sensitive areas like the face, palms, armpits, groin, genitals, and underneath the breasts. Here’s how ...

Protagonist Therapeutics (PTGX) stock jumps as Johnson & Johnson (JNJ) eyes a potential acquisition of the company in a deal ...

Several pharmaceutical companies have said they will sell drugs direct to patients in the U.S. and offered discounts ...

Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current ...

Johnson & Johnson raises 2025 sales forecast and beats quarterly estimates, while announcing plans to spin off its $9.2 ...